Scroll for more

news

Apr 19, 2018 announcements

BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development

BenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector.

Mar 28, 2018 announcements

Medical AI Award sets its sights on treating Parkinson's

A collaboration between Parkinson's UK and The Cure Parkinson's Trust (CPT) to identify new treatments for Parkinson's has been awarded the inaugural BenevolentAI Award. Presented through a competition run with the Association of Medical Research Charities (AMRC), the award offers a selected charity AI-driven R&D support from BenevolentAI, one of Europe's largest private AI companies.

Mar 15, 2018 announcements

BenevolentAI and group of UK charities partner to find a cure for blindness

BenevolentAI and Action Against AMD, a group of UK sight loss charities, have today announced their partnership to use BenevolentAI's technology to find treatments and a potential cure for the leading cause of blindness in the UK - 'age-related macular degeneration' (AMD).

Mar 9, 2018 articles

Biotech boss Jackie Hunter takes aim at male tech culture

Read Financial Times article about Jackie Hunter, BenevolentBio CEO about her quest to change behaviour and method.

Mar 5, 2018 articles

Could artificial intelligence cure ALS?

Dr Laura Ferraiuolo, Lecturer in Translational Neurobiology at SITraN in Sheffield and expert in ALS (Amyotrophic Lateral Sclerosis), disease talks about the advancement of research for ALS and the need for researchers to welcome new technologies to help them progress in finding potential new cures.

Mar 1, 2018 articles

Developing pharmaceuticals efficiently with artificial intelligence

Ken Mulvany talks to IBT about how the efficiency in the pharmaceutical industry can be increased by integrating AI methods.

Feb 27, 2018 articles

BenevolentAI's buy creates first AI firm capable of entire drug R&D

One of the largest AI enterprises in the world, BenevolentAI has acquired a research facility in Babraham,  FierceBiotech is reporting on it.

Feb 22, 2018 announcements

BenevolentAI acquires advanced Cambridge research facility to accelerate its AI-enabled drug development

Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development Cambridge research facility will advance BenevolentAI drug programmes into the clinic more quickly and at a much larger scale.

Feb 20, 2018 articles

Targeted protein degraders are redefining how small molecules look and act

Ian Churcher talks to chemical engineering news about targeted protein degradation.

Feb 13, 2018 articles

Digital Innovators: Q&A with BenevolentAI founder and chairman Ken Mulvany

Ken Mulvany talks to CityAm about AI, innovations and his ambitions for BenevolentAI

Feb 10, 2018 articles

BBC PODCASTS | The Shock of the New: Relationship between science, business and the consumer

Listen to Jackie Hunter taking part to the BBC podcast with Evan Davis to discuss the relationship between three important pillars of modern society: science, business and the consumer. Is the public right to be suspicious of business and the science it's selling? Why do some us fear GM foods, nanotechnology, AI and gene editing?

Nov 9, 2017 announcements

Annual award announced for medical research charities wishing to benefit from artificial intelligence

BenevolentAI, one of the world’s largest private AI companies, in partnership with the Association of Medical Research Charities (“AMRC”) announced today it has created a new award, the BenevolentAI Award, to help charities accelerate their medical research and potentially develop new treatments and therapies using artificial intelligence.

Oct 3, 2017 articles

How Close Are We to Curing ALS? A Review of Biotech’s Efforts

Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)

Aug 31, 2017 articles

This AI unicorn is disrupting the pharma industry in a big way

WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.

Aug 22, 2017 articles

BenevolentAI poaches drug discovery executive from GlaxoSmithKline

FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.

Aug 22, 2017 announcements

BenevolentAI hires Head of GSK Discovery Performance Unit as VP Drug discovery

BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.

Aug 11, 2017 articles

AI Hunts for New ALS Treatments

Our recent work with the Sheffield Institute of Translational Neuroscience (SITraN) on finding treatments for ALS is featured on Reuters UK. BenevolentBio CEO Professor Jackie Hunter and Dr Richard Mead of SITraN are interviewed about the effects of the disease and the process involved in finding the treatments.

Aug 8, 2017 announcements

BenevolentAI announces New York office opening and new hires

BenevolentAI, one of the world’s largest private AI companies, today announced it is expanding its footprint in the United States by opening an office in New York City and has made two significant hires - Keith Hall, from Google, and Daniel Neil, from the Institute of Neuroinformatics, that will form the foundation of the new New York BenevolentAI team.

Jul 28, 2017 articles

Unearthing Tomorrow's Medicine

Professor Jackie Hunter speaks to the Science Disrupt podcast about the potential to improve the drug discovery process with machine learning, as well as how AI is streamlining science more generally. In addition to opening up the potential for a whole new universe of potential findings, the podcast covers what this means for science as an evidence-based endeavour and whether it can help to reduce publication bias.

Jul 20, 2017 announcements

BenevolentAI hires new head of cheminformatics from the Institute of Cancer Research

One of the world’s largest private AI companies – BenevolentAI, that develops and applies artificial intelligence for scientific innovation, today announced it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics at BenevolentAI to VP Biomedical Informatics earlier in the year.

Jul 7, 2017 articles

Machine Learning and the march towards precision medicine

Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.

Jul 5, 2017 articles

Could AI help treat Motor Neurone Disease?

We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.